"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
| Descriptor ID |
D007167
|
| MeSH Number(s) |
E02.095.465.425
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 3 | 3 |
| 1999 | 0 | 3 | 3 |
| 2000 | 4 | 2 | 6 |
| 2001 | 2 | 5 | 7 |
| 2002 | 5 | 6 | 11 |
| 2003 | 4 | 5 | 9 |
| 2004 | 4 | 3 | 7 |
| 2005 | 6 | 2 | 8 |
| 2006 | 2 | 2 | 4 |
| 2007 | 3 | 3 | 6 |
| 2008 | 3 | 6 | 9 |
| 2009 | 12 | 7 | 19 |
| 2010 | 8 | 7 | 15 |
| 2011 | 8 | 7 | 15 |
| 2012 | 3 | 10 | 13 |
| 2013 | 10 | 7 | 17 |
| 2014 | 17 | 11 | 28 |
| 2015 | 7 | 5 | 12 |
| 2016 | 12 | 7 | 19 |
| 2017 | 18 | 13 | 31 |
| 2018 | 19 | 14 | 33 |
| 2019 | 14 | 14 | 28 |
| 2020 | 24 | 15 | 39 |
| 2021 | 15 | 22 | 37 |
| 2022 | 2 | 33 | 35 |
| 2023 | 3 | 19 | 22 |
| 2024 | 12 | 18 | 30 |
| 2025 | 19 | 7 | 26 |
| 2026 | 6 | 9 | 15 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
Established and Emerging Therapies for High-Risk Neuroblastoma. Paediatr Drugs. 2026 Mar; 28(2):159-175.
-
Immunotherapy of TSA-1.C4 or in combination with BNZ confers protection against Trypanosoma cruzi infection with a distinct cytokine response. Vaccine. 2026 Mar 19; 76:128296.
-
Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers. Nat Commun. 2026 Jan 03; 17(1):1193.
-
Standard complete blood count to predict long-term outcomes in febrile infection-related epilepsy syndrome (FIRES): A multicenter study. Epilepsia. 2025 Dec; 66(12):4780-4794.
-
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia. Blood. 2025 Jul 24; 146(4):437-455.
-
Molecular and clinical determinants of response to checkpoint inhibitor immunotherapy in glioblastoma. J Neurooncol. 2025 Oct; 175(1):453-461.
-
Combined Systemic Immunotherapy and Intrathecal Dexamethasone in Febrile Infection Related Epilepsy Syndrome. Ann Clin Transl Neurol. 2025 04; 12(4):871-875.
-
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell. 2024 07 08; 42(7):1202-1216.e8.
-
NK cells as powerful therapeutic tool in cancer immunotherapy. Cell Oncol (Dordr). 2024 Jun; 47(3):733-757.
-
Tumor inflammation-associated neurotoxicity. Nat Med. 2023 04; 29(4):803-810.